Form 4 Tracker
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA

64 insider filings · Latest: Jun 18, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Mar 17, 2026Mar 17 8:15 PMSabag Mark
Proposed Sale
62,102$30.14$1.9M

View →

Mar 5, 2026Mar 9 8:18 PMRichard D FrancisPresident and CEO
Sale
20,025$31.67$634.2K1,170,639(D)

View →

Mar 5, 2026Mar 9 8:16 PMChristine FoxEVP, U.S. Commercial
Sale
7,924$31.67$250.9K84,905(D)

View →

Mar 5, 2026Mar 9 8:14 PMEric A HughesSee "Remarks"
Sale
9,533$31.67$301.9K107,711(D)

View →

Mar 5, 2026Mar 9 8:12 PMRichard DaniellEVP, Europe Commercial
Sale
17,295$31.67$547.7K85,755(D)

View →

Mar 5, 2026Mar 9 8:10 PMPlacid JoverSee "Remarks"
Sale
14,150$31.67$448.1K6,774(D)

View →

Mar 5, 2026Mar 9 8:09 PMBrian SavageInterim Chief Legal Officer
Sale
1,127$31.67$35.7K10,914(D)

View →

Mar 5, 2026Mar 9 8:05 PMMatthew ShieldsEVP, Global Operations
Sale
17,295$31.67$547.7K9,989(D)

View →

Mar 4, 2026Mar 6 9:19 PMRichard D FrancisPresident and CEO
Sale
23,393$32.46$759.4K1,148,212(D)

View →

Mar 4, 2026Mar 6 9:17 PMRichard DaniellEVP, Europe Commercial
Sale
91,345$32.66$3.0M85,755(D)

View →

Mar 4, 2026Mar 6 9:09 PMEric A HughesSee "Remarks"
Sale
11,277$32.46$366.1K97,590(D)

View →

Mar 4, 2026Mar 6 9:05 PMChristine FoxEVP, U.S. Commercial
Sale
9,098$32.46$295.4K75,010(D)

View →

Mar 4, 2026Mar 6 9:03 PMBrian SavageInterim Chief Legal Officer
Sale
2,675$32.46$86.8K8,461(D)

View →

Mar 5, 2026Mar 5 10:49 PMShields Matthew
Proposed Sale
17,295$31.67$547.7K

View →

Mar 5, 2026Mar 5 10:43 PMJover Placid
Proposed Sale
14,150$31.67$448.1K

View →

Mar 5, 2026Mar 5 10:39 PMSavage Brian
Proposed Sale
1,127$31.67$35.7K

View →

Mar 5, 2026Mar 5 10:32 PMFox Christine
Proposed Sale
7,924$31.67$250.9K

View →

Mar 5, 2026Mar 5 10:26 PMFrancis Richard D
Proposed Sale
20,025$31.67$634.2K

View →

Mar 5, 2026Mar 5 10:13 PMHughes Eric A
Proposed Sale
9,533$31.67$301.9K

View →

Mar 5, 2026Mar 5 10:08 PMDaniell Richard
Proposed Sale
17,295$31.67$547.7K

View →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
May 14, 2026May 18 8:02 PMEvan LippmanEVP, Business Development
Option Exercise
85,84974,008(D)

View →

Mar 5, 2026Mar 9 8:23 PMMark SabagSee "Remarks"
Option Exercise
15,72347,170(D)

View →

Mar 5, 2026Mar 9 8:22 PMEliyahu Sharon KalifEVP, Chief Financial Officer
Option Exercise
19,91659,748(D)

View →

Mar 5, 2026Mar 9 8:19 PMAmir WeissChief Accounting Officer
Option Exercise
3,53710,613(D)

View →

Mar 5, 2026Mar 9 8:18 PMRichard D FrancisPresident and CEO
Option Exercise
42,452127,359(D)

View →

Mar 5, 2026Mar 9 8:16 PMChristine FoxEVP, U.S. Commercial
Option Exercise
17,81953,459(D)

View →

Mar 5, 2026Mar 9 8:14 PMEric A HughesSee "Remarks"
Option Exercise
19,65458,962(D)

View →

Mar 5, 2026Mar 9 8:12 PMRichard DaniellEVP, Europe Commercial
Option Exercise
17,29551,887(D)

View →

Mar 5, 2026Mar 9 8:10 PMPlacid JoverSee "Remarks"
Option Exercise
14,15042,453(D)

View →

Mar 5, 2026Mar 9 8:09 PMBrian SavageInterim Chief Legal Officer
Option Exercise
3,58010,740(D)

View →

Mar 5, 2026Mar 9 8:05 PMMatthew ShieldsEVP, Global Operations
Option Exercise
17,29551,887(D)

View →

Mar 4, 2026Mar 6 9:19 PMRichard D FrancisPresident and CEO
Option Exercise
50,223100,446(D)

View →

Mar 4, 2026Mar 6 9:19 PMRichard D FrancisPresident and CEO
Grant/Award
136,736136,736(D)

View →

Mar 4, 2026Mar 6 9:17 PMRichard DaniellEVP, Europe Commercial
Grant/Award
33,42433,424(D)

View →

Mar 4, 2026Mar 6 9:17 PMRichard DaniellEVP, Europe Commercial
Option Exercise
53,97340,923(D)

View →

Mar 4, 2026Mar 6 9:16 PMPlacid JoverSee "Remarks"
Grant/Award
37,98237,982(D)

View →

Mar 4, 2026Mar 6 9:14 PMMatthew ShieldsEVP, Global Operations
Grant/Award
33,42433,424(D)

View →

Mar 4, 2026Mar 6 9:13 PMMark SabagSee "Remarks"
Option Exercise
52,11337,202(D)

View →

Mar 4, 2026Mar 6 9:13 PMMark SabagSee "Remarks"
Grant/Award
30,38530,385(D)

View →

Mar 4, 2026Mar 6 9:11 PMEvan LippmanEVP, Business Development
Grant/Award
27,34727,347(D)

View →